Table 1.
Baseline characteristics of the NITRATE-CIN cohort
| Placebo (n = 321) | Inorganic Nitrate (n = 319) | |
|---|---|---|
| Age (years), mean ± SD | 71.2 ± 11.5 | 70.8 ± 11.8 |
| Sex, n (%) | ||
| Female | 80 (24.9) | 91 (28.5) |
| Male | 241 (75.1) | 228 (71.5) |
| Ethnicity, n (%) | ||
| Asian | 44 (13.7) | 58 (18.2) |
| Black | 31 (9.7) | 22 (6.9) |
| White | 242 (75.4) | 239 (74.9) |
| Unknown | 4 (1.3) | 0 |
| BMI (kg/m2), mean ± SD | 28.6 ± 5.8 | 28.1 ± 5.6 |
| Hypertension, n (%) | 248 (77.3) | 237 (74.3) |
| Hypercholesterolaemia, n (%) | 190 (59.0) | 196 (61.0) |
| Previous PCI, n (%) | 105 (32.7) | 107 (33.5) |
| Previous MI, n (%) | 104 (32.4) | 106 (33.2) |
| Diabetes, n (%) | 148 (46.1) | 146 (45.8) |
| Type I | 3 (0.9) | 3 (0.9) |
| Type II: Diet controlled, | 20 (6.2) | 21 (6.6) |
| Type II: Drug therapy, | 89 (27.7) | 94 (29.5) |
| Type II: Insulin | 36 (11.2) | 28 (8.8) |
| Presentation, n (%) | ||
| Unstable angina | 47 (14.6) | 50 (15.7) |
| NSTEMI | 274 (85.4) | 269 (84.3) |
| Smoking History, n (%) | ||
| Non- smoker | 134 (41.7) | 134 (42.0) |
| Previous smoker | 144 (44.9) | 141 (44.2) |
| Current smoker | 43 (13.4) | 44 (13.8) |
| Peripheral Vascular Disease, n (%) | 9 (2.8) | 17 (5.3) |
| Stroke, n (%) | 21 (6.5) | 17 (5.3) |
| CKD (eGFR < 60 mL/min), n (%) | 167 (52.1) | 191 (59.8) |
| LV impairment, n (%) | 118 (37.0) | 128 (40.0) |
| LV Ejection Fraction, mean ± SD | 48 ± 11 | 48 ± 12 |
| SBP (mmHg), mean ± SD | 132.8 ± 19.5 | 130.9 ± 21.0 |
| DBP (mmHg), mean ± SD | 72.3 ± 10.7 | 71.7 ± 10.6 |
| HR (bpm), mean ± SD | 70.3 ± 12.6 | 69.6 ± 12.0 |
NSTEMI, Non-ST Elevation Myocardial Infarction; PCI, Percutaneous Coronary Intervention; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate. Kidney insufficiency is defined as eGFR <90 mL/min/1.73 m2.